Clinical Scorecard: Evaluating the Role of Perilesional Edema Volume in Predicting Response to Stereotactic Radiosurgery in Melanoma Brain Metastases

At a Glance

Key Highlights

• SRT achieves local control rates of 75–95% with better quality of life compared to whole brain radiation therapy.
• Larger perilesional edema volumes correlate with higher intracranial progression risk and reduced response to SRT in brain metastases.
• This study assesses PEV as a predictive factor for intracranial response and survival in MBM treated with SRT plus systemic therapy.

Guideline-Based Recommendations

Diagnosis

• Use MRI with axial T1, T2-weighted, and FLAIR sequences for baseline imaging.
• Segment gross tumor volume on contrast-enhanced 3D T1-weighted images and perilesional edema volume on FLAIR/T2-weighted images using 3D Slicer software.
• Exclude lesions with overlapping edema or incompatible imaging for accurate volumetric assessment.

Management

• Administer stereotactic radiotherapy with total doses of 18–32.5 Gy over 1 to 5 fractions.
• Add a 3 mm isotropic margin to gross tumor volume to form planning target volume for treatment planning.
• Individualize dose, fractionation, and systemic therapy integration via multidisciplinary tumor board discussions.

Monitoring & Follow-up

• Perform brain contrast-enhanced MRI at baseline, 8–10 weeks post-SRT, then every 4–6 months or as clinically indicated.
• Evaluate intracranial objective response rate (iORR) using RANO criteria with independent review by radiation oncologist and neuroradiologist.
• Measure local intracranial progression-free survival (L-iPFS) from SRT to progression and overall survival (OS) from radiotherapy to death.

Risks

• Larger perilesional edema volume may predict poorer intracranial response and higher progression risk.
• Use of corticosteroids should be minimized (<2 mg/day dexamethasone) at MRI assessment to avoid confounding edema evaluation.

Patient & Prescribing Data

Patients with up to 5 melanoma brain metastases eligible for stereotactic radiotherapy and systemic therapy

SRT combined with systemic therapies including immune checkpoint inhibitors may improve local control and quality of life, but prognosis remains poor with median overall survival under one year; PEV measurement may help predict treatment response.

Clinical Best Practices

• Careful volumetric assessment of perilesional edema and gross tumor volume using standardized MRI protocols and software tools.
• Integration of imaging findings with clinical and molecular data to guide individualized treatment planning.
• Multidisciplinary tumor board involvement for optimizing SRT dose, fractionation, and systemic therapy combinations.
• Regular and standardized imaging follow-up to monitor response and progression.
• Minimize corticosteroid use during imaging to accurately assess edema volume.

References

• 3D Slicer software
• RANO criteria for brain metastases
• Declaration of Helsinki